Understanding Your Pathology Report and Staging
At a Glance
After surgery for testicular seminoma, your pathology report and TNMS staging guide your next steps. Key risk factors for relapse include a tumor size over 4cm and rete testis invasion. Low-risk patients often choose active surveillance with regular scans rather than additional treatment.
Once your surgery is complete, the focus shifts to your pathology report. This document is both a diagnosis and a roadmap.
The primary diagnostic step and treatment is a radical inguinal orchiectomy, typically an outpatient surgery where the affected testicle is removed through a small incision in the groin. Recovery generally takes a few weeks. If you choose, a prosthetic testicle can often be placed during the same procedure to maintain normal appearance [1]. The surgery itself is therapeutic because it removes the source of the cancer, but it is also diagnostic because it provides the tissue needed to stage the disease accurately [2][3].
Decoding the TNMS Staging System
Testicular cancer uses a unique staging system called TNMS (8th edition). Understanding these four letters allows you to audit your own report and participate in your care decisions [4].
- T (Tumor): This describes how far the tumor has grown locally.
- N (Nodes): This tells you if the cancer has spread to nearby lymph nodes, usually determined by a CT scan of the abdomen [5].
- M (Metastasis): This indicates if the cancer has spread to distant organs, like the lungs [5].
- S (Serum Tumor Markers): This is unique to testicular cancer and is measured via a blood test [4].
The “S” Category: Why Your Blood Work Matters
The S category is determined by your blood levels of three specific markers after your surgery: LDH, hCG, and AFP [6].
- S0: All markers are within normal limits after surgery [6].
- S1–S3: Markers remain elevated at various levels [6].
For a diagnosis of “pure” seminoma, your AFP (alpha-fetoprotein) should be normal. If your AFP is elevated, your care team will usually manage the disease as a “non-seminoma.” While it requires a different treatment path, non-seminoma is also highly curable [1][6].
Identifying Risk Factors in Stage I
If your cancer is Stage I (it hasn’t spread beyond the testicle), your doctor will look for “high-risk” features that might predict if the cancer could return. The two most significant factors for seminoma are:
- Tumor Size > 4cm: Larger tumors are statistically more likely to have microscopic spread that isn’t visible on initial scans [7][4].
- Rete Testis Invasion: The rete testis is a network of small tubes at the exit of the testicle. If the pathology shows the cancer has grown into this area, it is considered a secondary risk factor for relapse [4][8].
Empowering Your Next Step
If your report shows a small tumor (under 4cm) and no rete testis invasion, you are likely at a very low risk for relapse. Many patients in this category choose active surveillance, which involves regular scans and blood work instead of more chemotherapy or radiation [9][10]. Understanding these details in your report helps you and your doctor decide whether to watch closely or proceed with extra preventative treatment [11].
Common questions in this guide
What does rete testis invasion mean on my pathology report?
Why do my blood tumor markers matter for staging?
What if my AFP level is elevated after surgery?
What makes a Stage I seminoma high-risk for relapse?
What is active surveillance for testicular cancer?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my pathology report show any evidence of 'rete testis invasion'?
- 2.What was the exact size of the tumor in my final pathology report? Is it larger than 4cm?
- 3.Are my tumor markers (hCG, LDH, and AFP) back to normal range now that the surgery is over?
- 4.Based on my 'S' score and 'T' staging, do you consider me high-risk for the cancer coming back?
- 5.If my AFP level was elevated, does that mean I might have a 'non-seminoma' component?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Testicular Cancer, Version 2.2015.
Motzer RJ, Jonasch E, Agarwal N, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2015; (13(6)):772-99 doi:10.6004/jnccn.2015.0092.
PMID: 26085393 - 2
Distinguishing epigenetic features of preneoplastic testis tissues adjacent to seminomas and nonseminomas.
Gainetdinov IV, Kondratieva SA, Skvortsova YV, et al.
Oncotarget 2016; (7(16)):22439-47 doi:10.18632/oncotarget.7074.
PMID: 26843623 - 3
Management of stage I testicular cancer.
Padayachee J, Clark R, Warde P, Hamilton RJ
Current opinion in urology 2022; (32(1)):17-23 doi:10.1097/MOU.0000000000000942.
PMID: 34772865 - 4
Updates in 2022 on the staging of testicular germ cell tumors.
Canete Portillo S, Rais-Bahrami S, Magi-Galluzzi C
Human pathology 2022; (128()):152-160 doi:10.1016/j.humpath.2022.07.009.
PMID: 35926809 - 5
Updates in Staging and Reporting of Testicular Cancer.
Magers MJ, Idrees MT
Surgical pathology clinics 2018; (11(4)):813-824 doi:10.1016/j.path.2018.07.005.
PMID: 30447843 - 6
Reprint of: Updates in 2022 on the staging of testicular germ cell tumors.
Canete Portillo S, Rais-Bahrami S, Magi-Galluzzi C
Human pathology 2023; (133()):153-161 doi:10.1016/j.humpath.2023.02.010.
PMID: 36898947 - 7
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans JL, Sylvester R, Anson-Cartwright L, et al.
European urology oncology 2024; (7(3)):537-543 doi:10.1016/j.euo.2023.10.014.
PMID: 37951820 - 8
Prognostic factors for relapse in stage I testicular seminoma: tumor size and rete testis invasion revisited.
Aparicio J
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018; (20(10)):1358-1359 doi:10.1007/s12094-018-1861-0.
PMID: 29744734 - 9
Management of Low-Stage Testicular Seminoma.
Pearce SM, Liauw SL, Eggener SE
The Urologic clinics of North America 2015; (42(3)):287-98.
PMID: 26216816 - 10
Stage I seminoma: Outcome of different treatment modalities and changes in patterns of care. A single institution experience.
Mahmoud Sayed M, Nasr AM, Saad Eldin IM, Abdelazim YA
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2023; (95(1)):11057 doi:10.4081/aiua.2023.11057.
PMID: 36924377 - 11
Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients.
John A, Baumgart A, Worst T, Heinzelbecker J
Urologia internationalis 2018; (100(3)):279-287 doi:10.1159/000486343.
PMID: 29514158
This page explains testicular seminoma pathology terminology for educational purposes only. Your urologist and oncologist are the best sources for interpreting your specific report and staging.
Get notified when new evidence is published on Testicular seminomatous germ cell tumor.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.